BrainStorm

News

News

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Brainstorm Issues 2017 Letter to Shareholders
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 29, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to Shareholders from its President and CEO, Chaim Lebovits Dear
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 20, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will provide a corporate
View HTML
Toggle Summary BrainStorm's Abstracts on Phase 2 NurOwn® Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 29, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that two scientific posters describing innovative biomarker data from the
View HTML
Toggle Summary New Peer Reviewed Publication Shows That BrainStorm's NurOwn® Has a Unique miRNA Signature
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 9, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that a study profiling NurOwn ® 's unique miRNA signature has been
View HTML
Toggle Summary BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
Eyal Rubin, VP and Head of Corporate Treasury at Teva, is Third Senior Appointment at Brainstorm in 2017 HACKENSACK, N.J. and PETACH TIKVAH, Israel , Nov. 2, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for
View HTML
Toggle Summary BrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn® Technology for Parkinson's Disease And ALS
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 23, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has received Notice of Allowance from the United States Patent Office
View HTML
Toggle Summary BrainStorm Announces Third Quarter 2017 Financial Results
Conference Call with Management to Discuss Recent Corporate Progress at 8:30am Eastern Time Today HACKENSACK, N.J. and PETACH TIKVAH, Israel , Oct. 17, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative
View HTML
Toggle Summary BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS
Trial supported by a $16M non-dilutive grant from CIRM Top-line data are expected in 2019 HACKENSACK, N.J. and PETACH TIKVA, Israel , Oct. 16, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that the first patients have been enrolled in the Phase 3 clinical
View HTML
Toggle Summary Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17
Conference Call and Live Webcast at 8:30am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , Oct. 3, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases , will announce financial results
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Sept. 27, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases announced today that it will be presenting at the 2017 Disruptive Growth Company Showcase
View HTML
Toggle Summary BrainStorm Announces Second Quarter 2017 Financial Results
Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 15, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for
View HTML
Toggle Summary Brainstorm to Host Second-Quarter 2017 Earnings Teleconference and Provide Important Corporate Updates, on Wednesday, August 16
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 10, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases , will announce financial results for the three and six months ended June 30, 2017 and
View HTML
Toggle Summary BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs
Mary Kay Turner brings 25+ years Biotech and Pharmaceutical Experience in Healthcare Advocacy and Policy; Prior Positions Include Head of Patient Advocacy and Communications at Mitsubishi Tanabe Pharma America and Head of State Government Affairs and Advocacy at Bristol-Myers Squibb Company
View HTML
Toggle Summary BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel , July 25, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed a definitive agreement with the University of
View HTML
Toggle Summary Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel , July 21, 2017 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded
View HTML
Toggle Summary BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel , July 18, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed definitive agreements with Massachusetts General
View HTML
Toggle Summary Worldwide Clinical Trials Selected by BrainStorm as CRO for Phase 3 NurOwn Trial in ALS
HACKENSACK, N.J. and PETACH TIKVAH, Israel , July 3, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has selected Worldwide Clinical Trials ("Worldwide") as its
View HTML
Toggle Summary BrainStorm to Provide Corporate Update at the BIO International Convention
HACKENSACK, N.J. and PETACH TIKVAH, Israel , June 14, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Company will present a corporate overview at the BIO
View HTML
Toggle Summary BrainStorm Awarded $2.1 Million Non-Dilutive Grant for 2017 by the Israel Innovation Authority
HACKENSACK, N.J. and PETACH TIKVAH, Israel , June 13, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd.
View HTML
Toggle Summary BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC
HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 22, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the Company will present data from its Phase 2 clinical study of NurOwn® in
View HTML
Toggle Summary BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS Study
HACKENSACK, N.J. , PETACH TIKVA, Israel and DUARTE, Calif. , May 16, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has begun training the cell manufacturing team at
View HTML
Toggle Summary BrainStorm Announces First Quarter 2017 Financial Results and Provides Corporate Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 15, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the first quarter ending March 31, 2017 .
View HTML
Toggle Summary BrainStorm to Present at Two Scientific Conferences in May
HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 1, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present data from its Phase 2 clinical study of
View HTML
Toggle Summary Brainstorm Cell Therapeutics to Present at ARM's 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
HACKENSACK, N.J. and PETACH TIKVAH, Israel , April 20, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will present at the
View HTML
Toggle Summary BrainStorm Announces Publication of NurOwn® Autism Research Study
Preclinical Findings Show Potential for Human Benefit HACKENSACK, N.J. and PETACH TIKVAH, Israel , April 19, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that a preclinical
View HTML
Toggle Summary BrainStorm Announces Financial Results for 2016 and Provides Business Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 30, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the year ended December 31, 2016 .
View HTML
Toggle Summary BrainStorm CEO to Present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 22, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will provide an update on
View HTML
Toggle Summary BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
Brings 10+ years Biotech and Pharmaceutical Industry Experience; Prior Academic Positions Include Consultant Neurologist Role at Mount Sinai Hospital, Toronto, Canada. HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 6, 2017 /CNW/ --  BrainStorm Cell Therapeutics Inc.
View HTML
Toggle Summary BrainStorm Announces MOU with Tel Aviv Sourasky Medical Center to Make NurOwn® Available to Patients as a Hospital Exemption Product
Tel Aviv Sourasky Medical Center (Ichilov) Is Also Expected to be a Treatment Center in Planned Phase 3 Trial of NurOwn In ALS HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 1, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell
View HTML
Toggle Summary BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Feb. 27, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointments of June S. Almenoff , M.D., Ph.D., FACP, and Arturo O.
View HTML
Toggle Summary BrainStorm Seeking Approval To Distribute NurOwn® in Canada
Signs agreement with CCRM for regulatory support of ALS treatment TORONTO , HACKENSACK, N.J. and PETACH TIKVAH, Israel , Feb. 21, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, has signed an
View HTML
Toggle Summary City of Hope to Manufacture NurOwn® for Brainstorm's Phase 3 ALS Clinical Trial
HACKENSACK, N.J. and PETACH TIKVA, Israel and DUARTE, Calif. , Feb. 16, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it plans to contract with City of Hope's Center for
View HTML
Toggle Summary BrainStorm CEO to Present at the BIO CEO & Investor Conference
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Feb. 6, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will provide a corporate
View HTML
Toggle Summary BrainStorm Announces Validation of NurOwn® Cryopreservation Process
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Jan. 30, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has validated its cryopreservation process for NurOwn ® in preparation
View HTML
Toggle Summary BrainStorm CEO to Present at the Phacilitate Cell & Gene Therapy World Conference 2017 in Miami
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Jan. 17, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will give a presentation
View HTML
Toggle Summary BrainStorm CEO to Present at the 9th Annual Biotech Showcase
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Jan. 5, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will provide a corporate
View HTML
Tools
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds